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Inhibition of gene expression through siRNAs is a tool increasingly used for the study of gene function in model systems, including
transgenic mice. To achieve perdurable effects, the stable expression of siRNAs by an integrated transgenic construct is necessary.
For transgenic siRNA expression, promoters transcribed by either RNApol II or III (such as U6 or H1 promoters) can be used.
Relatively large amounts of small RNAs synthesis are achieved when using RNApol III promoters, which can be advantageous in
knockdown experiments. To study the feasibility of H1 promoter-driven RNAi-expressing constructs for protein knockdown in
transgenic mice, we chose IKK1 as the target gene. Our results indicate that constructs containing the H1 promoter are sensitive
to the presence of prokaryotic sequences and to transgene position effects, similar to RNApol II promoters-driven constructs. We
observed variable expression levels of transgenic siRNA among different tissues and animals and a reduction of up to 80% in IKK1
expression. Furthermore, IKK1 knockdown led to hair follicle alterations. In summary, we show that constructs directed by the H1
promoter can be used for knockdownof genes of interest in different organs and for the generation of animalmodels complementary
to knockout and overexpression models.
1. Introduction
RNA interference (RNAi) is an evolutionarily conserved
mechanism of regulation of gene expression in eukaryotic
cells. It is based on the degradation of mRNAs by the action
of complementary small interfering RNAs (siRNAs) and the
concomitant decrease in the synthesis of the correspond-
ing protein. siRNAs, approximately 21-nucleotide long, are
produced in the cell from longer double-stranded RNAs
or can be synthesised from small hairpin RNAs (shRNAs)
transcribed from genetic constructs produced in the labo-
ratory and introduced into the cells. RNAi has been used
for the functional knockdown of specific proteins in several
experimental systems, from cultured cells [1] to complete
organisms, including mammals [2]. Typically, knockdown
transgenic animals are produced by the introduction of
the RNAi construct in the cells by lentiviral vectors or by
pronuclear microinjection of one-cell embryos. It is also
possible to generate knockdown animals from genetically
modified ES cells [3]; for a review about the application of
this technology to living mammals, see [2].
RNAi technology represents an interesting tool in func-
tional genetic studies for several reasons. Firstly, it is poten-
tially applicable for decreasing the expression of the protein
of interest in species for which ES cells are not available.
Secondly, RNAi usually results in partial inhibition of the
expression (typically, in the range of 60–90%) and thus
allows the generation of graded hypomorphic phenotypes,
which are usually impossible to generate by ES gene targeting
technologies [3, 4]. These hypomorphic animal models are
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complementary, and sometimesmore informative, to loss-of-
function knockoutmodels, especially when gene inactivation
causes embryonic lethality. In addition, both inducible and
reversible expressions of siRNA can be achieved by using
the same approaches used in other transgenic systems, such
as Cre recombinase-controlled transgene expression and
tetracycline responsive elements [5–8]. Finally, RNAi is a
promising therapeutic tool that could be used for the silenc-
ing of dominant mutant alleles [9, 10], for silencing of mutant
transcripts originated from alleles carrying triplet expansion
in the 3󸀠-untranslated region [11], or for the treatment of solid
tumors in patients [12].
Different types of RNA polymerases (RNApol) are
responsible for the production of different types of RNAs
in eukaryotic cells. While RNApol II transcribes mRNA-
coding genes, some microRNAs and other noncoding RNAs,
RNApol III synthesizes, among others, transfer RNAs, 5S
ribosomal RNA, and other short noncoding RNAs required
in all cell types, such as U6 RNA—a component of
spliceosomes—and H1 RNA—the RNA component of the
RNase P ribonuclease, implicated in tRNAmaturation.Thus,
RNApol III products are involved in primary cellular pro-
cesses such as transcription, RNA processing, and protein
synthesis [13, 14]. For experiments involving siRNA synthesis,
both RNApol II- and RNApol III-dependent promoters have
been used. Constructs containing promoters transcribed by
RNApol II are used when a tight regulation of transgene
expression is desired (i.e., tissue-specific or inducible expres-
sion) [7, 15]. In general, as RNApol III promoters are
shorter than RNApol II promoters, they are more suitable for
constructs with length limitations, like those carried by viral
vectors. Among the RNApol III promoters, mouse U6 and
human H1 gene promoters are the most commonly used in
transgenic constructs. Considering the expression pattern of
these genes, it is generally accepted that their promoters drive
ubiquitous and high-level expression of transgenes. In this
regard, it is interesting to note that although there are several
published reports describing the specific knockdown of the
gene of interest using RNApol III promoters, the expression
pattern of these transgenes has not been studied in detail in
most of the studies. Other aspects of RNApol III-containing
transgenes that have proven important in classic transgenic
constructs containing RNApol II promoters, including sen-
sitivity to integration position effects and the inhibitory
influence of prokaryotic sequences [16], also remain poorly
analysed.
The IKK1 protein is a key regulator of the NF𝜅B signalling
pathway that plays a crucial role in epithelial physiology.
IKK1 gene inactivation in mice leads to lack of keratinocyte
differentiation, to defective function of the skin and other
stratified epithelia, and to newborn lethality [17, 18]. Mice
with IKK1 inactivation restricted to keratinocytes also die
at birth [19]. These phenotypes preclude the study of IKK1
function in adult mice by using knockout models. The study
of other animal models (i.e., IKK1+/− mice and transgenic
mice overexpressing IKK1) has shed some light into addi-
tional functions of IKK1, indicating that IKK1 is important
for the development of epidermal cancer [20–22].
To gain insight into IKK1 function in adult skin and
to determine the feasibility of achieving a partial loss of
function by RNAi expression in skin and other organs of
transgenic mice, we microinjected a H1 promoter-driven
RNAi construct directed against IKK1 into one-cell embryos.
We detected in these transgenic mice variable expression
levels of IKK1 siRNA in several tissues of different transgenic
lines, in contrast to the roughly homogeneous activity of
endogenous H1 promoter, suggesting that the expression
of this type of transgenic constructs is subject to position
effects. RT-qPCR analysis of IKK1 expression indicated a
variable decrease in mRNA levels, ranging from 0 to 80%.
In addition, some transgenic mice showed alterations in hair
growth and in hair folliclemorphology after depilation. Taken
together, our results indicate the feasibility of RNApol III-
transcribed genetic constructs for knockdown of specific
proteins in different tissues of transgenic mice, although
with variable efficiency when comparing different tissues or
different animals.
2. Materials and Methods
2.1. IKK1 Interfering Plasmids. For IKK1 interference, two
different 64 bp long synthetic oligonucleotides containing
IKK1-specific sequences were subcloned between the BglII
and HindIII sites of pSuper vector (Oligoengine; Seattle,
WA), downstream of the human H1 promoter, resulting in
IKK1-SuperA and IKK1-SuperB plasmids. A Control-Super
plasmid, containing a scrambled nonspecific sequence
that did not have relevant homology for IKK1 or other
known murine sequences, was also constructed. The general
structure for these oligonucleotides was BglII linker—
sense sequence (ss)—hairpin spacer—antisense sequence
(as)—end of transcription signal—HindIII linker (i.e.,
5󸀠-GATCCCC-ss-TTCAAGAGA-as-TTTTTGGAAA-3󸀠).
Sense sequences for each plasmid are shown in Figure 1(a).
2.2. Cell Culture andTreatments. HEK-293T cells were grown
in DMEM (Gibco-BRL; Life Technologies) supplemented
with 10% of FCS and antibiotics. Exponentially growing p60
culture plates were transfected by the calcium phosphate
method with a total amount of 6 𝜇g of DNA containing
both pRC-𝛽actin-HA-IKK1 (a plasmid for the expression
of a HA-tagged IKK1 protein [23]) and one of the pSuper-
derivatives described previously at different ratios (Figure 1).
As an additional control, we also performed cotransfections
with an empty pSuper vector, unable to produce any shRNA.
After 48 hours, cells were harvested and frozen for posterior
analysis by northern or western blots.
2.3. Generation and Genotyping of IKK1-siRNA Transgenic
Mice. Transgenic mice were generated by microinjection
of the indicated constructs into (C57BL/6J × DBA/2J) F2
embryos using standard techniques [24] and transgenic lines
were maintained by crosses with (C57BL/6J × DBA/2J)
F1 mice. IKK1-siRNA transgenic mice were genotyped by
southern blot or PCR analysis of tail genomic DNA. In
southern blots, genomic DNAs were digested with XbaI
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Figure 1: IKK1 silencing in HEK293T transiently transfected cells. (a) Sequences included in pSuper plasmid vector for the production of
shRNAs designed to knockdown IKK1 expression. Two IKK1 specific oligonucleotides (A andB) and one control scrambled sequence (C)were
cloned in pSuper and tested in transfected cells. Nucleotide numbers refer to RefSeq: MN 007700.2. (b) Northern blot analysis of transiently
transfected HEK293T cells hybridized with a probe specific for IKK1. Plates were cotransfected with a plasmid for the expression of IKK1 and
the indicated pSuper-derivatives; “none” indicates that an empty plasmid was used. (c) Western blot analysis of IKK1 produced in transfected
cells. In (b) and (c), each lane contains pooled RNAs or proteins extracts from two different plates. Ratios between the IKK1 expression
















Figure 2: Generation of H1-IKK1-siRNA transgenic mice. (a) Schematic representation of the transgenes microinjected in one-cell mouse
embryos. Transgene A1 is a 285 bp fragment containing the H1 promoter (white box) and the DNA oligonucleotide for shRNA synthesis
(filled in black). Transgene A2 contained, in addition, the rest of the pSuper plasmid in its 3󸀠 end (3234 bp total length).White arrows indicate
the primers used for PCR-genotyping of transgenic mice. Relevant restriction sites are indicated. (b) Southern blot analysis of transgenic
founders. The transgene injected (A1 or A2) and the name of the transgenic lines (L1 to L7) are indicated. Asterisks indicate founder mice
that did not transmit the transgene to their progeny and were not included in further analysis. In the lane marked as C it was loaded DNA
from a nontransgenic control mouse and the amount of fragment A2 corresponding to 20 copies per haploid genome. Figures in the left of
the blot indicate fragment size in kbp.
(that cuts once in transgene A2) and the 32P-labelled
fragment A1 was used as a probe (Figure 2(a)). For PCR
amplification, we used primers for the amplification of a
221 bp-fragment from both transgenes (forward primer: 5󸀠-
GTCATCAACCCGCTCCAAGG-3󸀠; reverse primer: 5󸀠-GA-
CTGACGGGGGATCTGTGG-3󸀠). We used nontransgenic
littermates as control animals. All experimental procedures
were performed according to European and Spanish laws and
regulations.
2.4. Protein and RNA Analysis. Whole-cell protein extracts
from mouse organs and tissues were prepared as described
in [25]. Protein content was determined by the Bradford
colorimetric protein assay (BioRad Laboratories; Hercules,
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CA, USA). For the western blot shown in Figure 1(c), we
used an antibody specific for HA epitope (Roche; Basel,
Switzerland).
For northern blot assays, the organs studied were dis-
sected from mice and immediately frozen in liquid nitrogen.
Total RNAs from murine tissues were extracted with an
acid guanidinium thiocyanate-phenol-chloroform mixture,
as described in [26]. RNAs from cultured cells were extracted
using TRIzol reagent (Invitrogen; Life Technologies Ltd.
Paisley, UK) according to manufacturer’s instructions. RNAs
were quantified by 260 nm spectrophotometry and their
quality was evaluated by electrophoresis.
To detect siRNA, 100 𝜇g of total RNA was loaded on 15%
polyacrylamide −8M urea gels (UreaGel System, National
Diagnostics; Atlanta, USA) and separated by electrophore-
sis. Gels were transferred onto nylon membranes (Amer-
sham Hybond-N+, GE Healthcare; Uppsala, Sweden) using
wet transfer. We used as a probe a DNA oligonucleotide
complementary to the IKK1 siRNA A (Figure 1(a)). These
oligonucleotides were radiolabeled in their 5󸀠-end by using
polynucleotide kinase (Roche) and 𝛾32P-dATP. Band sizes
were estimated by comparison with the bands of Decade
Marker (Ambion; Austin, TX).
Equal loading was confirmed by using a U6 probe. We
used Molecular Imager FX imaging system and the Quantity
One software (BioRad Laboratories) for quantification of the
intensity of the bands.
For the study of H1 RNA expression, a 345 bp fragment of
the RPPH1 gene was PCR amplified and used as a probe [27].
2.5. Histological Analysis of Tissues. Mouse tissues were
dissected and immediately fixed in 10% buffered formalin
or 70% ethanol and embedded in paraffin. Five 𝜇m thick
sections were used for H&E staining.
2.6. qRT-PCR Analysis. RNAs were purified with RNeasy
Mini Kit (Qiagen; Hilden, Germany) and their integrity was
analysed in a 2100 Bioanalyzer (Agilent; Santa Clara, CA,
USA). cDNAswere obtained using aTranscriptor kit (Roche).
For qRT-PCR, we used Taqman MGB probes with 6-FAM
reporter dye (Applied Biosystems, Life Technologies Corpo-
ration; Carlsbad, CA, USA).We used probes specific for IKK1
(Mm00432529 m1) and for TBP (TATA binding protein,
Mm00446937 m1). TBP values were used as a control for
normalization.
We analysed samples in triplicate and at least two times
in a Rotor-gene thermocycler (Qiagen; Germantown, MD).
We quantified the IKK1 expression level in each sample as a
percentage of the TBP-normalised average value obtained for
IKK1 in control mice.
2.7. Mice Depilation. Mice were shaved with a clipper and
then the stubble was removed using Veet depilatory cream
(Slough, UK) following the instructions of the vendor.
3. Results
3.1. Selection of an Effective Sequence for Interfering
IKK1 Expression. We used the software available at the
Oligoengine web site (http://www.oligoengine.com/) for the
selection of oligonucleotide sequences likely to knockdown
IKK1 expression. We selected the sequences A and B shown
in Figure 1(a) that did not show homology with other genes
in the murine genome, thus lowering the chance of off-target
effects. As a negative control, we used a sequence not
complementary to IKK1 or to any other sequence found in
the mouse genome (oligonucleotide C, originating Control-
Super construct, Figure 1(a)). To evaluate the efficiency of
these constructs for IKK1 knockdown, we cotransfected
HEK293T cells with different ratios of plasmids directing the
expression of an HA-taggedmurine IKK1 protein and each of
the shRNAs described in Figure 1(a). As an additional control
we also transfected HEK293T cells with the HA-tagged IKK1
expression plasmid and an unmodified (empty) pSuper
vector, unable to produce any shRNA. Analysis of IKK1
mRNA (Figure 1(b)) and protein (Figure 1(c)) expression
48 hours after-transfection showed that both IKK1-SuperA
and IKK1-SuperB constructs were able to knock down
the target gene at the mRNA and protein levels, being
IKK1-SuperA more efficient. Furthermore, its efficiency was
dose-dependent in the range tested.
3.2. Generation of Transgenic Mice. To assess whether H1-
driven constructs are useful to knockdown gene expression
in the skin and other organs of transgenic mice, we generated
transgenic mice carrying the IKK1-SuperA construct, the
most efficient design for IKK1 knockdown in our in vitro
test. Since silencing by proximal prokaryotic sequences has
not been studied for RNApol III-driven constructs, we
microinjected both the whole linearized IKK1-SuperA plas-
mid including the prokaryotic sequences (a EcoRI-linearized
3234 bp-long construct, transgene A2, Figure 2(a)) and a
smaller fragment containing only the H1 promoter and the
DNA fragment coding for the shRNA (a 285 bp EcoRI-Hind
III fragment, transgene A1, Figure 2(a)).
Microinjection of fragments A1 and A2 into the pronuclei
of (C57BL/6J × DBA/2J) F2 embryos yielded 99 and 49
newborn mice, respectively. Out of them, six newborn mice
that had beenmicroinjectedwith transgeneA1 and three with
transgeneA2 resulted positive in a PCR analysis for transgene
presence (not shown). Transgenic status was further verified
by southern blot analysis using as a probe the A1 fragment
labelledwith 32P (Figure 2(b)). GenomicDNAswere digested
with XbaI, which cuts once into the A2 transgene and does
not cut into the A1 transgene. Therefore, a 3.2 kbp band is
expected in head-to-tail array integrations of the transgene
A2 if the digestion is complete and the XbaI site located in the
3󸀠-region of the transgene is conserved in all the integrated
copies. The presence of bands of higher molecular weight
suggests an incomplete digestion or the lack of the XbaI site
in some of the copies. A1 founders would render a band of
variable size, depending on the location of the XbaI sites
surrounding the integrated transgene array. Differences in
the intensity of the bands obtained in founder mice would
reflect differences in the number of integrated copies of the
transgene for each founder. Southern blot analysis indicated
that A2 transgenic founder mice carried more copies than
A1 founders. Except for the two mice marked with asterisks
in Figure 2(b), all founders transmitted the transgene upon
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breeding, thus originating four transgenic lines for the A1
transgene (L1 to L4) and three for the A2 transgene (L5 to
L7). Transgenic mice of all lines were viable and fertile and
did not show any overt phenotype.
3.3. Expression of IKK1 siRNA in Transgenic Mice. Trans-
gene expression was first analysed in back skin, brain, and
liver of all transgenic lines by northern blot using a 32P-
labelled oligonucleotide A probe and a U6 RNA (a ubiq-
uitously expressed component of the spliceosome) probe
for loading normalization. Representative results are shown
in Figure 3(a), and a summary of the normalized signals
obtained for the different lines in several northern blots is
shown in Figure 3(b).
We found substantial differences in the expression level
of the siRNA among the different transgenic lines, being L1
the line with the highest expression level. Lines bearing the
transgene containing pSuper backbone sequences (lines L5
to L7) showed lower expression level than lines lacking these
plasmid sequences (L1 to L4). These results indicate that, as
described for transgenes transcribed by RNApol II [16], it is
advisable to delete plasmid sequences in order to get high
expression levels in transgenes containing the H1 promoter.
In addition, the relative expression level of the transgene was
not the same in the tissues studied in the different transgenic
lines, as might be expected for transgenes driven by the
promoter of H1 (a ubiquitously expressed small RNA gene).
Expression in brain was higher than in back skin in some
lines—five times in line L1 and two times in line L2—but both
organs expressed the transgene at the same level in line L4
(Figure 3(b)).These results suggest that transgenic constructs
containing the H1 promoter are sensitive to position effects,
in a similar way as classical RNApol II-dependent transgenic
constructs.
We selected the L1 line to analyse in more depth the
expression pattern of the transgene. We extracted RNAs
from 12 different organs and analysed by northern blot
the amount of siRNA produced in hemizygous animals. As
shown in Figure 3(c), the expression levels varied greatly in
the different tissues tested, with differences of up to 10-fold.
This could be due to differences in the transcription rate
of H1 promoter in different organs, in accordance with the
described cell type specificity of transcription for RNApol
III-dependent genes [13]. Alternatively, the activity of the
enzymatic machinery needed for the production of siRNA
from the shRNA could be different in different organs. In
order to test these possibilities, we studied the expression level
of endogenous H1 gene in a similar set of organs and found
marked variations between them (Figure 3(d)), although to a
lesser extent than those found for the IKK1 siRNA transgene.
In addition, the differences in H1 expression did not parallel
those found for IKK1 siRNA. These data suggest that the
differences in transgene expression could be caused, at least
partially, by intrinsic differences in the rate of transcription
of transgenic constructs containing H1 promoter in different
cell types. However, as there is not an accurate correlation
between the expression level of IKK1 siRNA and H1 in the
organs tested, other factors might additionally be affecting
transgene expression.
3.4. Reduced Expression of IKK1 in Transgenic Mice. To assess
the capability of theH1-driven transgene to knockdown IKK1,
we studied IKK1 expression in some organs from L1 trans-
genic mice. We selected back skin (as IKK1 absence leads to
profound phenotypic alterations in skin [17, 18]); brain, which
is the organ with the highest level of IKK1 siRNA expression
(Figure 3(c)); and liver, which expresses a remarkable high
level of IKK1 mRNA (not shown). We performed qRT-
PCR analysis of IKK1 expression in organs from several L1
transgenic mice and nontransgenic littermates. A summary
of the results obtained is shown in Figures 4(a)–4(c). Of note,
we found for the three organs tested greater variability of
IKK1mRNAexpression levels inmice transgenic for the IKK1
siRNA construct than in nontransgenic littermates. Some
transgenic mice expressed IKK1 roughly at the same level
thanWtmice (black triangles in Figures 4(a)–4(c)) and other
showed decreased expression in relation to Wt mice (less
than 65% of the average expression in Wt mice; see grey
triangles in Figure 4(a)). The proportion of transgenic mice
with decreased IKK1 expression varied from 20% in liver to
47% in back skin.When considering only values formicewith
decreased expression, IKK1 mean expression was between
35 and 55% of the values found in Wt mice, depending
on the organ (Figure 4(d)). These results indicate a variable
efficiency in IKK1 knockdown between different mice, as not
all of them showed decreased IKK1 mRNA. It is interesting
to note that there is no apparent correlation between the
expression level of IKK1 siRNA and knockdown efficiency in
the tested organs, as brain showed around 5-fold more IKK1
siRNA expression than back skin or liver (Figure 3(c)), but
this difference of transgene expression did not correlate with
IKK1 inhibition efficiency (Figure 4).
Immunohistochemical staining of paraffin sections of
skin with an antibody specific for IKK1 revealed variations
in the intensity of staining along the histological section
both for Wt and Tg mice. Interestingly, under the same
reaction conditions, some of the Tg mice (5 out of 11) showed
weaker staining or more marked variations than Wt mice,
probably reflecting a greater variability in IKK1 expression
in skin keratinocytes of L1 transgenic mice (not shown) as a
consequence of IKK1 inhibition in a fraction of the cells.
Taken together, our qRT-PCR and immunohistochemical
analyses indicate that some L1 transgenic mice show a
variable reduction in IKK1 expression in the different organs
tested; this reduction does not seem to be uniform, as it did
not affect every transgenic mouse and it did not affect every
organ in a given mouse. In addition, even when considering
an organ with clear IKK1 expression inhibition such as skin,
not all the cells seem to be affected to the same extent.
3.5. Phenotypic Alterations in IKK1 siRNA Transgenic Mice.
Considering the decreased amount of IKK1 in some trans-
genic mice and the profound phenotypic consequences
caused by the absence of IKK1 in mice [17, 18], we studied
if IKK1 siRNA transgenic mice presented any phenotypic
alterations. Careful examination of litters and posterior
genotyping revealed that around 50% of the transgenic mice
presented some irregularity in themacroscopic appearance of
hair and a lower density in pelage; these features made some
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Figure 3: Expression of IKK1 siRNA in transgenic mice. (a) Upper part: representative examples of the northern blots performed for analysis
of IKK1 siRNAexpression in organs fromH1-IKK𝛼-siRNA transgenic lines. LaneC is a positive control that containsRNA from the transfected
cells loaded in the first lane of Figure 1(b). The black arrow indicates the position of the specific 21-nucleotide band. Samples from wild-type
animals gave no signals for IKK1 siRNA. The motilities of 20-, 30-, 40-, and 50-nucleotide RNA fragments are indicated. Lower part: the
same blots were hybridized with a probe specific for U6 RNA, as a loading control. (b) Relative expression levels of IKK1 siRNA in different
transgenic lines; siRNA intensities were normalized against their correspondingU6 signals and presented as a percentage of the value obtained
for brain in line L1. (c) Relative expression level of IKK1 siRNA in organs of L1 transgenic mice. Signals obtained with an U6 probe were used
for normalization. (d) H1 expression in control mice. The same blot was hybridized with a 7S-specific probe, as a loading control. In the
histogram of the right, the relative expression of H1 normalized against 7S signals in different organs of control mice is shown. B: brain; Bs:
back skin; H: heart; K: kidney; L: liver; Lu: lung; M: muscle; P: pancreas; Pr: prostate; S: spleen; St: stomach; T: thymus; Ts: tail skin.
transgenic mice distinguishable fromwild-type littermates to
an expert eye.This slight hair coat phenotype was observed in
the first hair growth cycle but disappeared and was no longer
detectable after weaning. In order to reveal hypothetical mal-
function of hair follicles in siRNA IKK1Tgmice, we subjected
hair follicles to stress by removing the hair fromback skin.We
depilated 11 transgenic mice and 9 nontransgenic littermates
at the age of 24 days, when hair follicles are at the end of
the resting phase (telogen) of the first growth cycle. All the
control mice showed a rapid hair regrowth, evident 4 days
after depilation, when new hair began to cover the skin again;
by 11 days after depilation, hair growth was complete, and
the skin was totally covered with new hair (see examples
in Figure 5(a)). By contrast, hair regrowth was delayed in
7 (64%) of the transgenic mice at 11 days after-depilation,
ranging from an evident delay in growth (e.g., L1 transgenic
mice in the left photograph of Figure 5(a)) to a complete
lack of hair coat regrowth (see L1 mice in the right image of
Figure 5(a)).
In the histological analysis of the back skin of these mice,
we occasionally observed some distorted hair follicles in both
Tg and Wt mice, probably because of the stress associated
to depilation. The percentage of altered hair follicles was
greater in Tg mice than in Wt littermates (on average, 6.3%






























































































Figure 4: Reduced IKK1 mRNA expression in some H1-IKK1-siRNA transgenic mice. (a) IKK1 qRT-PCR analysis in back skin. Each value is
presented as a percentage against the media obtained for wild-type mice. Diamonds indicate the values obtained for Wt mice and triangles
those obtained for Tg mice. Grey triangles represent Tg mice with diminished (65% or below) IKK1 expression level. The number of mice
analysed belonging to each category is indicated. ((b), (c)) Similar analysis as in (a), but for brain and liver, respectively. (d) Bar chart of the
expression level of those L1 mice with diminished IKK1 expression level.
in Tg versus 2.9% inWt mice). These abnormal follicles were
characterised by distorted shapes and follicle degeneration,
accompanied by dermal deposition of melanin and local
infiltration of mononuclear cells (Figure 5(b)) around the
follicular debris. In addition, transgenic mice presented
irregularities in the distribution of melanin in the medulla
of the hair shaft and the presence of some morphologically
distorted hair shafts, which did not correspond to any of the
usual hair types found in control mice—guard, awl, auchene,
and zig-zag hairs—(not shown).
In summary, siRNA IKK1 Tg mice showed more severe
alterations in the shape of hair shafts, and in the growth
and shape of hair follicles, than those found in wild-type
littermates after depilation. It is interesting to note that we
did not detect decreased levels of IKK1 mRNA in all the
mice that showed phenotypic alterations. Considering the






Figure 5: Most H1-IKK1-siRNA transgenic mice showed delayed hair follicle regrowth and hair follicle anomalies after depilation. (a) Slight
(left) and severe (right) delay in the regrowth of hair follicles 11 days after depilation in transgenic mice. (b) Hematoxylin and eosin staining
of skin histological sections. Morphological alterations in hair follicles of transgenic mice (black arrows) and dermal melanin deposition (red
arrowheads) are shown. Bar: 80𝜇m.
observed variability in IKK1 knockdown efficiency between
different organs and mice, it could well be that knockdown
efficiency varies also between neighbour cells within a given
organ, as described by others [28].This situation would result
in sporadic cells or groups of cells with diminished IKK1
expression, so that theywill cause local phenotypic alterations
that could not be translated to a detectable decrease in IKK1
mRNA level in a tissue extract.
4. Discussion
In this report, we have studied transgenic mice expressing a
siRNA specific for IKK1 under the transcriptional control of
human H1 promoter. We generated these mice by microin-
jecting different fragments of a pSuper-derived construct
containing the interference sequence into one-cell embryos.
We studied transgene expression in brain, back skin, and
liver of several lines and found that those lines that included
the pSuper backbone in the injected fragment expressed
poorly, and frequently only in a fraction of the tissues
tested. By contrast, those lines lacking the plasmid backbone
expressed the transgene at higher levels than lines carrying
the plasmid backbone. Even more, some lines lacking the
plasmid backbone expressed the transgene in all the tissues
tested. Therefore, one of the conclusions drawn from this
work is that it seems to be a good policy to delete prokaryotic
plasmid sequences in transgenes transcribed by RNApol III,
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as it was also described for RNApol II-transcribed transgenes
at the beginning of the transgenesis era [16].
We studied the expression pattern of the transgene in
a broader set of tissues and organs from mice of L1 line,
which showed the highest expression level in brain. In this
line, every organ analysed expressed the transgene, although
with marked differences in the level of expression. As these
differences in expression could reflect intrinsic variations
in the activity of H1 promoter in different cell types, we
determined the abundance of H1 RNA in a similar set
of samples. In accordance with the presumed ubiquitous
expression pattern of H1 promoter, we found a detectable
signal in all the organs tested. Of note, H1 expression level
also varied among the organs, although with a different
pattern than the siRNA IKK1 transgene. From all these
data, we conclude that the transgene we used (and probably
others containing the human H1 promoter or other RNApol
III-transcribed promoters) is similar in several aspects to
more classic RNApol II-transcribed transgenes. Firstly, our
transgene is prone to position effects, displaying different
expression patterns in different transgenic lines; secondly, its
expression is not proportional to transgene copy number;
and finally, it is sensitive to the presence of prokaryotic
plasmid sequences. In order to overcome this position effect
sensitivity and to get more reproducible expression patterns,
it would be interesting to test the use of bigger and more
active versions of the H1 promoter [29], or to include general
or tissue-specific enhancers for increasing expression [30].
In addition, the use of insulators could also result in better
expression of RNApol III-driven interfering constructs, as it
was previously found for RNApol II constructs [31, 32].
siRNA IKK1 transgene results in a lower steady-state
amount of IKK1 mRNA in different organs in some of
the transgenic samples studied. Surprisingly, the average
reduction in the expression level of IKK1 mRNA in those
animals with reduced expression was roughly similar in all
the tissues tested (brain, liver, and back skin, Figure 4(d))
even though the IKK1 siRNAwas expressed at different levels
in different tissues (see Figure 3(c)). It is also remarkable that
IKK1 expression was variably decreased in each individual
mouse.Thus, we found that, for back skin, the same transgene
integration lowered IKK1 mRNA expression to less than
20% of the average level found in Wt mice in one mouse,
to around 55–60% in seven mice of the same line, and
did not decrease IKK1 mRNA at all in the other nine. The
question why IKK1 expression is not reduced to a similar
extent in every tissue of every transgenic mouse of the same
line is an intriguing one. In this context, other interfering
transgenes have been described which also show variable
efficiency between different animals [33], between different
tissues or cell types [34–36] or even in the same cell type,
giving rise to a mosaic gene expression knockdown [28, 37].
Differences among tissues could have to do, at least partially,
with differences in the ratio between siRNA and target
mRNA or with intrinsic differences in the functioning of the
interference machinery. Anyway, it seems that inhibition of a
gene product by transgenic expression of a siRNA is subjected
to more variability than classical overexpression of a protein
of interest in transgenesis experiments. The differences we
find between transgenic animals of the same line could also
be due to genetic heterogeneity between mice, since our
transgenic founders were F2 mice between C57BL/6J and
DBA/2J strains and they were subsequently bred to F1 mice
of that background, resulting in a mixed genotype different
for each mouse. However, the fact that we did not find a
consistent degree of inhibition in different organs of a given
mouse is against this idea. Therefore, although variations
in knockdown efficiency could have to do with genetic
variability, there are probably additional players. Variability
in knockdown efficiency seems to be a commonphenomenon
in interfering transgenicmice [28, 33–37], which could reflect
some randomness in the silencing process. In this regard, it
would be interesting to generate additional transgenic mice
in order to determine if knockdown variability is diminished
by improvements in transgenic design, by using pure inbred
strains of mice or by increasing transgenic dosage (i.e., in
homozygous animals or in compound hemizygous of several
insertions).
It is worth noting that phenotypic alterations occurred
in IKK1 siRNA mice when hair follicles were challenged
by a depilatory treatment. The hair follicle phenotype we
found has not been previously reported in the animal models
hitherto published with altered expression of IKK1, that is,
general and stratified epithelia-specific knockouts, as well
as skin overexpression of IKK1 [17–20, 22]. These follicle
alterations could be related to the multiple and complex
functions of IKK1 in epidermal physiology. On the one hand,
IKK1 gene inactivation leads to such profound alterations in
embryonic skin that newborn mice die and the study of hair
follicles in adult life is therefore precluded. In addition, the
IKK1 protein has different targets and functions depending
on its location in the cytoplasm or in the nucleus [38, 39].
Finally, as some of the functions of IKK1 are not cell-
autonomous [40], dermal IKK1 can compensate for the lack of
IKK1 in keratinocytes. Thus, the specific phenotype we have
found may arise because of the simultaneous decrease, albeit
at not well-defined rates, of IKK1 function in both dermal
and epidermal cells. Interestingly, alterations in the shape
of hair follicles are also found in mice expressing mutant
forms of IKK1 in skin keratinocytes (our unpublished results).
Therefore, the hair follicle phenotype described in this report
is probably caused by changes in IKK1 activity, and not by
other nonspecific effects of siRNA, as it has been described in
other experiments involving RNA interference [41].
Taken together, the results described in this paper rep-
resent an example of the potential of the technology of
RNA interference in transgenic mice. This kind of trans-
genic mice can be considered as complementary to other
genetically modified models (mice with general and tissue-
specific knockout—or overexpression—of the protein under
study), and actually different models frequently render dif-
ferent valuable functional information. Our results also give
interesting clues, to those aiming to knockdown a gene
product using RNApol III-dependent transgenes, regarding
the design of the transgene to be injected. In summary, we
show that transgenic constructs directed by the H1 promoter
can be used for the knockdownof genes of interest in different
organs and for decreasing the level of the corresponding
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mRNAs in transgenic mice generated by pronuclear microin-
jection, and for the generation of relevant animal models
complementary to knockout or overexpression transgenic
mice in deciphering protein functions.
Abbreviations
IKK: Kinase of the inhibitor of NF𝜅B
NF𝜅B: Nuclear factor 𝜅B
RNAi: RNA interference
RNApol: RNA polymerase
shRNA: Small hairpin RNA




The authors declare that there is no conflict of interests
regarding the publication of this paper.
Acknowledgments
The authors would like to thank I. de los Santos and F.
Sanchez-Sierra for excellent technical assistance and the per-
sonnel of the CIEMAT Animal Unit for the care of the mice
used in this work. This research was supported by Grants
from the Spanish government (Ministerio de Economı́a y
Competitividad: SAF2010-22156 to Angel Ramirez and PI-
10/01480 toM. Llanos Casanova and Instituto de SaludCarlos
III: RD12/0036/0009) and from the Comunidad Autónoma
de Madrid (52011/BMD2470).
References
[1] J. Harborth, S. M. Elbashir, K. Bechert, T. Tuschl, and K.Weber,
“Identification of essential genes in cultured mammalian cells
using small interfering RNAs,” Journal of Cell Science, vol. 114,
no. 24, pp. 4557–4565, 2001.
[2] K. Podolska and P. Svoboda, “Targeting genes in living mam-
mals by RNA interference,” Briefings in Functional Genomics,
vol. 10, no. 4, pp. 238–247, 2011.
[3] T. Kunath, G. Gish, H. Lickert, N. Jones, T. Pawson, and
J. Rossant, “Transgenic RNA interference in ES cell-derived
embryos recapitulates a genetic null phenotype,” Nature
Biotechnology, vol. 21, no. 5, pp. 559–561, 2003.
[4] M. T. Hemann, J. S. Fridman, J. T. Zilfou et al., “An epi-allelic
series of p53 hypomorphs created by stable RNAi produces
distinct tumor phenotypes in vivo,”Nature Genetics, vol. 33, no.
3, pp. 396–400, 2003.
[5] G. Tiscornia, V. Tergaonkar, F. Galimi, and I. M. Verma, “CRE
recombinase-inducible RNA interferencemediated by lentiviral
vectors,” Proceedings of the National Academy of Sciences of the
United States of America, vol. 101, no. 19, pp. 7347–7351, 2004.
[6] P. K. Premsrirut, L. E. Dow, S. Y. Kim et al., “A rapid and scalable
system for studying gene function in mice using conditional
RNA interference,” Cell, vol. 145, no. 1, pp. 145–158, 2011.
[7] K. McJunkin, A. Mazurek, P. K. Premsrirut et al., “Reversible
suppression of an essential gene in adult mice using transgenic
RNA interference,” Proceedings of the National Academy of
Sciences of the United States of America, vol. 108, no. 17, pp. 7113–
7118, 2011.
[8] R. A. Dickins, K. McJunkin, E. Hernando et al., “Tissue-specific
and reversible RNA interference in transgenic mice,” Nature
Genetics, vol. 39, no. 7, pp. 914–921, 2007.
[9] L. Jiang, H. Zhang, A. M. Dizhoor et al., “Long-term RNA
interference gene therapy in a dominant retinitis pigmentosa
mouse model,” Proceedings of the National Academy of Sciences
of the United States of America, vol. 108, no. 45, pp. 18476–18481,
2011.
[10] C. Nobrega, I. Nascimento-Ferreira, I. Onofre et al., “Silencing
mutant ataxin-3 rescues motor deficits and neuropathology in
Machado-Joseph disease transgenic mice,” PLoS One, vol. 8,
Article ID e52396, 2013.
[11] K. Sobczak, T. M. Wheeler, W. Wang, and C. A. Thornton,
“RNA interference targeting CUG repeats in a mouse model of
myotonic dystrophy,” Molecular Therapy, vol. 21, pp. 380–387,
2013.
[12] M. E. Davis, J. E. Zuckerman, C. H. J. Choi et al., “Evidence
of RNAi in humans from systemically administered siRNA via
targeted nanoparticles,” Nature, vol. 464, no. 7291, pp. 1067–
1070, 2010.
[13] R. J. White, “Transcription by RNA polymerase III: more
complex than we thought,” Nature Reviews Genetics, vol. 12, no.
7, pp. 459–463, 2011.
[14] G. Dieci, G. Fiorino, M. Castelnuovo, M. Teichmann, and A.
Pagano, “The expanding RNA polymerase III transcriptome,”
Trends in Genetics, vol. 23, no. 12, pp. 614–622, 2007.
[15] X.-G. Xia, H. Zhou, E. Samper, S. Melov, and Z. Xu, “Pol
II-expressed shRNA knocks down Sod2 gene expression and
causes phenotypes of the gene knockout inmice,” PLoS genetics,
vol. 2, no. 1, p. e10, 2006.
[16] R. D. Palmiter and R. L. Brinster, “Germ-line transformation of
mice,” Annual Review of Genetics, vol. 20, pp. 465–499, 1986.
[17] Q. Li, Q. Lu, J. Y. Hwang et al., “IKK1-deficient mice exhibit
abnormal development of skin and skeleton,” Genes and Devel-
opment, vol. 13, no. 10, pp. 1322–1328, 1999.
[18] K. Takeda, O. Takeuchi, T. Tsujimura et al., “Limb and skin
abnormalities in mice lacking IKKalpha,” Science, vol. 284, pp.
313–316, 1999.
[19] R. Gareus, M. Huth, B. Breiden et al., “Normal epider-
mal differentiation but impaired skin-barrier formation upon
keratinocyte-restricted IKK1 ablation,” Nature Cell Biology, vol.
9, no. 4, pp. 461–469, 2007.
[20] E. Park, F. Zhu, B. Liu et al., “Reduction in I𝜅B kinase 𝛼
expression promotes the development of skin papillomas and
carcinomas,” Cancer Research, vol. 67, no. 19, pp. 9158–9168,
2007.
[21] B. Liu, E. Park, F. Zhu et al., “A critical role for I𝜅Bkinase𝛼 in the
development of human and mouse squamous cell carcinomas,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 103, no. 46, pp. 17202–17207, 2006.
[22] J. P. Alameda, R.Moreno-Maldonado,M. J. Fernández-Aceñero
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